Eikon Therapeutics, Inc.

8-K · eikn-20260530.htm iXBRL

0001861123 2026-05-30 2026-05-30 0001861123 dei:FormerAddressMember 2026-05-30 2026-05-30

  
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): May 30, 2026

  
  
 EIKON THERAPEUTICS, INC.
 (Exact name of Registrant as Specified in Its Charter)
  
  

 Delaware

 001-43085

 84-2807586

 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

  

  

  

  

  

 230 Harriet Tubman Way

  

 Millbrae , California

  

 94030

 (Address of Principal Executive Offices)

  

 (Zip Code)

  

 Registrant’s Telephone Number, Including Area Code: (341) 777-0566

  

  

 Not Applicable

  

 (Former Name or Former Address, if Changed Since Last Report)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

 Trading
Symbol(s)

  

Name of each exchange on which registered

 Common Stock, $0.0001 par value per share

  

 EIKN

  

 The Nasdaq Stock Market LLC

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

 Item 7.01 Regulation FD Disclosure.
 On May 30, 2026, Eikon Therapeutics, Inc. (the “Company”) updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 The information in this Item 7.01, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in this Item 7.01, including 99.1 hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.
 Item 8.01 Other Events.
 On May 30, 2026, the Company issued a press release announcing updated data on its Phase 2 trial of EIK1001 in first-line patients with stage 4 non-small cell lung cancer and new and updated data on its Phase 1/2 trial of EIK1003 in patients with advanced solid tumors, which were presented at the 2026 American Society of Clinical Oncology Annual Meeting. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
 Item 9.01 Financial Statements and Exhibits.
 (d) Exhibits
  

 Exhibit
 Number

 Description

 99.1

  

 Eikon Therapeutics, Inc. Corporate Presentation as of May 30, 2026.

 99.2

  

 Press Release dated May 30, 2026.

 104

 Cover Page Interactive Data File (embedded within the Inline XBRL document).

  
  

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

  

 EIKON THERAPEUTICS, INC.

  

  

  

  

 Date:

 June 1, 2026

 By:

 /s/ Alfred Bowie, Ph.D.

  

  

  

 Alfred Bowie, Ph.D.
 Chief Financial Officer